Dr. Hu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000
Summary
- Lymphoma and apheresis attending at Levine Cancer Institute/Atrium Health. Board certified in Hematology, Medical Oncology, and Internal Medicine
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Vanderbilt University Medical CenterResidency, Internal Medicine, 2011 - 2014
University of California San Francisco School of MedicineClass of 2011
Certifications & Licensure
NC State Medical License 2017 - 2025
TX State Medical License 2015 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Conquer Cancer Merit Award ASCO, Conquer Cancer Foundation, 2016
Clinical Trials
- Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects Start of enrollment: 2016 Dec 01
- Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma Start of enrollment: 2019 Feb 19
Publications & Presentations
PubMed
- 13 citationsEqual access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphomaBei Hu, Danielle Boselli, Lisa M. Pye, Tommy Chen, Rupali Bose
Cancer. 2021-11-01 - 39 citationsThe MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu
Clinical Cancer Research. 2021-09-15 - 19 citationsPhase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.Bei Hu, Anas Younes, Jason R. Westin, Francesco Turturro, Linda Claret
Leukemia & Lymphoma. 2018-04-01
Journal Articles
- De Novo CD5+ diffuse large B cell lymphoma: clinic characterististics and clinical outcomes in the Rituximab era2. Hu B, Nastoupil LJ, Westin JR, Logavi S, Thakral B, Fayad LE, Hagemeister G, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y, Leukemia and Lymphoma, 9/18/2019
- Standardizing opioid prescribing practices for cancer-related pain via a novel interactive documentation template at a public hospital3. Nusrat M, Parkes A, Kieser R, Hu B, Farhat D, Rieber A, Ma H, Journal of Oncology Practice, 6/21/2019
- A tale of two eras: the story of autologous stem cell transplantation with and without thiotepa for primary central nervous system lymphomaHu B, Biology of Blood and Marrow Transplantation, 5/2019
- Join now to see all
Press Mentions
Downregulation of SENP1 Suppresses LPS-Induced Macrophage Inflammation by Elevating Sp3 SUMOylation and Disturbing Sp3-NF-κB InteractionNovember 15th, 2020
High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients with DLBCLDecember 12th, 2019
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
